The Riboflavin Biosynthetic Pathway As a Novel Target for Antifungal Drugs Against Species

Overview

Journal mBio

Publisher American Society for Microbiology

Specialty Microbiology

Date 2024 Oct 15

PMID 39404356

Authors

Jana Nysten

Arne Peetermans

Dries Vaneynde

Stef Jacobs

Liesbeth Demuyser

Patrick Van Dijck

Affiliations

Soon will be listed here.

Abstract

Importance: species are a common cause of invasive fungal infections. , in particular, poses a significant threat to immunocompromised individuals. This opportunistic pathogen typically lives as a commensal on mucosal surfaces of healthy individuals but it can also cause invasive infections associated with high morbidity and mortality. Currently, there are only three major classes of antifungal drugs available to treat these infections. In addition, the efficacy of these antifungal agents is restricted by host toxicity, suboptimal pharmacokinetics, a narrow spectrum of activity, intrinsic resistance of fungal species, such as , to certain drugs, and the acquisition of resistance over time. Therefore, it is crucial to identify new antifungal drug targets with novel modes of action to add to the limited armamentarium.

References

Gietz R, Schiestl R . High-efficiency yeast transformation using the LiAc/SS carrier DNA/PEG method. Nat Protoc. 2007; 2(1):31-4. DOI: 10.1038/nprot.2007.13. View

Fonzi W, Irwin M . Isogenic strain construction and gene mapping in Candida albicans. Genetics. 1993; 134(3):717-28. PMC: 1205510. DOI: 10.1093/genetics/134.3.717. View

Pericolini E, Gabrielli E, Ballet N, Sabbatini S, Roselletti E, Decherf A . Therapeutic activity of a Saccharomyces cerevisiae-based probiotic and inactivated whole yeast on vaginal candidiasis. Virulence. 2016; 8(1):74-90. PMC: 5963212. DOI: 10.1080/21505594.2016.1213937. View

Robbins N, Wright G, Cowen L . Antifungal Drugs: The Current Armamentarium and Development of New Agents. Microbiol Spectr. 2016; 4(5). DOI: 10.1128/microbiolspec.FUNK-0002-2016. View

Averianova L, Balabanova L, Son O, Podvolotskaya A, Tekutyeva L . Production of Vitamin B2 (Riboflavin) by Microorganisms: An Overview. Front Bioeng Biotechnol. 2020; 8:570828. PMC: 7693651. DOI: 10.3389/fbioe.2020.570828. View

Clark C, Drummond R . The Hidden Cost of Modern Medical Interventions: How Medical Advances Have Shaped the Prevalence of Human Fungal Disease. Pathogens. 2019; 8(2). PMC: 6631793. DOI: 10.3390/pathogens8020045. View

Pierce C, Lopez-Ribot J . Candidiasis drug discovery and development: new approaches targeting virulence for discovering and identifying new drugs. Expert Opin Drug Discov. 2013; 8(9):1117-26. PMC: 3984500. DOI: 10.1517/17460441.2013.807245. View

Romisch-Margl W, Eisenreich W, Haase I, Bacher A, Fischer M . 2,5-diamino-6-ribitylamino-4(3H)-pyrimidinone 5'-phosphate synthases of fungi and archaea. FEBS J. 2008; 275(17):4403-14. DOI: 10.1111/j.1742-4658.2008.06586.x. View

Denning D . Global incidence and mortality of severe fungal disease. Lancet Infect Dis. 2024; 24(7):e428-e438. DOI: 10.1016/S1473-3099(23)00692-8. View

10.

Deorukhkar S, Saini S, Mathew S . Non-albicans Candida Infection: An Emerging Threat. Interdiscip Perspect Infect Dis. 2014; 2014:615958. PMC: 4227454. DOI: 10.1155/2014/615958. View

11.

Byrne K, Wolfe K . The Yeast Gene Order Browser: combining curated homology and syntenic context reveals gene fate in polyploid species. Genome Res. 2005; 15(10):1456-61. PMC: 1240090. DOI: 10.1101/gr.3672305. View

12.

Pfaller M, Castanheira M, Lockhart S, Ahlquist A, Messer S, Jones R . Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol. 2012; 50(4):1199-203. PMC: 3318516. DOI: 10.1128/JCM.06112-11. View

13.

Vale-Silva L, Sanglard D . Tipping the balance both ways: drug resistance and virulence in Candida glabrata. FEMS Yeast Res. 2015; 15(4):fov025. DOI: 10.1093/femsyr/fov025. View

14.

Foraker A, Khantwal C, Swaan P . Current perspectives on the cellular uptake and trafficking of riboflavin. Adv Drug Deliv Rev. 2003; 55(11):1467-83. DOI: 10.1016/j.addr.2003.07.005. View

15.

Lienhart W, Gudipati V, Macheroux P . The human flavoproteome. Arch Biochem Biophys. 2013; 535(2):150-62. PMC: 3684772. DOI: 10.1016/j.abb.2013.02.015. View

16.

Liu S, Hu W, Wang Z, Chen T . Production of riboflavin and related cofactors by biotechnological processes. Microb Cell Fact. 2020; 19(1):31. PMC: 7017516. DOI: 10.1186/s12934-020-01302-7. View

17.

Abbas C, Sibirny A . Genetic control of biosynthesis and transport of riboflavin and flavin nucleotides and construction of robust biotechnological producers. Microbiol Mol Biol Rev. 2011; 75(2):321-60. PMC: 3122625. DOI: 10.1128/MMBR.00030-10. View

18.

Katsipoulaki M, Stappers M, Malavia-Jones D, Brunke S, Hube B, Gow N . and : global priority pathogens. Microbiol Mol Biol Rev. 2024; 88(2):e0002123. PMC: 11332356. DOI: 10.1128/mmbr.00021-23. View

19.

Wilson A, Pardee A . Regulation of flavin synthesis by Escherichia coli. J Gen Microbiol. 1962; 28:283-303. DOI: 10.1099/00221287-28-2-283. View

20.

Kainz K, Bauer M, Madeo F, Carmona-Gutierrez D . Fungal infections in humans: the silent crisis. Microb Cell. 2020; 7(6):143-145. PMC: 7278517. DOI: 10.15698/mic2020.06.718. View